Semaglutide 3mg: Which Medicine Is It, and What Does It Do?

Is the 3mg semaglutide tablet used for weight loss?

No. The 3mg tablet is the introductory dose of Rybelsus, which is licensed by the MHRA for glycaemic control in adults with type 2 diabetes. It is not licensed or intended for weight management. Patients prescribed Rybelsus typically take the 3mg dose for the first month as a tolerability period, before their prescriber moves them up through 7mg and then 14mg.

This matters because semaglutide (the active ingredient in both Rybelsus and Wegovy) is a GLP-1 receptor agonist that works on appetite and blood-sugar regulation regardless of the brand. Some people assume that if Wegovy causes weight loss, any semaglutide product must do the same. The licensing does not work that way. Rybelsus was tested and approved specifically in a diabetes population, at doses studied for that purpose. Using it outside that licensed indication is not something a responsible prescriber would do for weight loss when a licensed alternative exists.

The NHS patient information on semaglutide sets out both products clearly and is worth reading if you want a plain-English overview of how the two differ. If you have been prescribed Rybelsus for diabetes, you can read more about semaglutide to understand how the medicine works before speaking to your prescriber about whether anything about your treatment plan should change.

What does the Wegovy tablet dose ladder actually look like?

The oral semaglutide product licensed for weight management is the Wegovy tablet, which the MHRA approved in June 2026, making the UK the first country in Europe to authorise it. Its dose schedule is completely separate from Rybelsus: it starts at 1.5mg, steps up to 4mg, then 9mg, and reaches a 25mg maintenance dose, with at least a month spent at each level.

The 3mg, 7mg, and 14mg strengths that appear in a search for oral semaglutide tablets are Rybelsus strengths, and if you want to understand what the 3 ml semaglutide format involves, that page explains it in full. They are not rungs on the Wegovy weight-loss ladder, and they should never be treated as such. Picking up a 3mg Rybelsus tablet to start a weight-loss course would mean taking an unlicensed dose of the wrong product. Our full Wegovy guide explains the approved schedule in detail.

The phase 3 trial data for the Wegovy tablet (OASIS 4, 64 weeks, 307 adults with obesity or overweight plus at least one weight-related condition) showed an average weight loss of around 13.6% compared with roughly 2.4% on placebo. Among participants who adhered fully throughout the trial, the figure was closer to 17%. These are the only canonical figures you should see quoted for this medicine; any other number has not been verified against the trial record. The phase 3 evidence for semaglutide covers both injection and tablet trial results if you want to compare them side by side.

Who qualifies for the Wegovy tablet on a private prescription?

The MHRA's licensed indication for the Wegovy tablet covers adults with a BMI of 30 or above, or adults with a BMI of 27 to 29.9 who have at least one weight-related condition, such as high blood pressure, raised cholesterol, prediabetes, or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. A BMI figure alone does not determine whether the medicine is right for you; a prescriber looks at the full clinical picture, including your health history and any other medicines you take.

The Wegovy tablet is not available on the NHS at the time of writing, a NICE appraisal would be needed first. That means access currently runs through private prescriptions from registered clinics and pharmacies. Practically speaking, if you take your tablet first thing in the morning before the rest of the household stirs, it is easier to manage the 30-minute wait before any food or drink; that small habit makes adherence considerably simpler.

If you are curious about what a clinical consultation involves and what questions a prescriber typically covers, our treatment overview explains the process from start to finish. For pricing context, the Wegovy prices page sets out what private treatment typically costs and what a legitimate quote should include.

Are there any safety points specific to oral semaglutide?

Semaglutide (whether injected or swallowed) carries a GI-led side-effect profile. Nausea, loose stools, constipation, and indigestion are the most frequently reported, particularly in the early weeks of treatment or after a dose step. In the OASIS 4 trial, 74% of participants on oral semaglutide reported a gastrointestinal side effect at some point, compared with 42% on placebo. Most were mild to moderate and settled with time.

The MHRA has highlighted acute pancreatitis as a known but infrequent risk across GLP-1 medicines. Severe abdominal pain that radiates to the back, especially alongside vomiting, is a reason to seek urgent medical attention rather than wait. The Yellow Card scheme lets patients report suspected side effects directly to the MHRA, which is particularly valuable for a newly approved medicine still building its real-world safety record.

The Wegovy tablet is not recommended during pregnancy, while breastfeeding, or for those trying to conceive. It is also not licensed for under-18s. Oral semaglutide must be taken on an empty stomach with a small amount of plain water and nothing else for at least 30 minutes afterwards, other medicines, coffee, and food all reduce absorption significantly. Your Patient Information Leaflet covers this in full; follow it carefully. For a broader look at how the semaglutide injection compares with the tablet on practical grounds, the semaglutide overview is a useful starting point.